| Literature DB >> 25367589 |
Eiichi Suehiro1, Hiroyasu Koizumi, Yuichi Fujiyama, Michiyasu Suzuki.
Abstract
For severe traumatic brain injury (TBI) patients, no effective treatment method replacing hypothermia therapy has emerged, and hypothermia therapy still plays the major role. To increase its efficacy, first, early introduction is important. Since there are diverse pathologies of severe TBI, it is necessary to appropriately control the temperature in the hypothermia maintenance and rewarming phases by monitoring relative to the pathology. Currently, hypothermia is considered appropriate for severe TBI patients requiring craniotomy for removal of hematoma, while induced normothermia is appropriate for severe TBI patients with diffuse brain injury. Induced normothermia is expected to exhibit a cerebroprotective effect equivalent to hypothermia, as well as reduce the complexity of whole-body management and systemic complications. According to the Japan Neurotrauma Data Bank of the Japan Society of Neurotraumatology, the brain temperature was controlled in 43.9% of severe TBI patients (induced normothermia: 32.2%, hypothermia: 11.7%) in Japan. Brain temperature management was performed mainly in young patients, and the outcome on discharge was favorable in patients who received brain temperature management. Particularly, patients who need craniotomy for removal of hematoma were a good indication of therapeutic hypothermia. Improvement of therapeutic outcomes with widespread temperature management in TBI patients is expected.Entities:
Mesh:
Year: 2014 PMID: 25367589 PMCID: PMC4533346 DOI: 10.2176/nmc.st.2014-0160
Source DB: PubMed Journal: Neurol Med Chir (Tokyo) ISSN: 0470-8105 Impact factor: 1.742
Fig. 1.Progress of body temperature and intracranial pressure (ICP) during hypothermia therapy. In rewarming phase, ICP was elevated suddenly, and rewarming was suspended. Once ICP decreased, rewarming could be restarted.
Clinical outcome according to pathophysiology in previous studies [29,41)]
| Diffuse injury | Evacuated mass lesion | |||||||
|---|---|---|---|---|---|---|---|---|
| NABIS: H II
[ |
The Japan Neurotrauma Data Bank
[ |
NABIS: H II
[ |
The Japan Neurotrauma Data Bank
[ | |||||
| Favorable outcome | Mortality | Favorable outcome | Mortality | Favorable outcome | Mortality | Favorable outcome | Mortality | |
| Induced normothermia | 50.0% | 9.0% | 33.3% | 33.3% | 31.0% | 39.0% | 26.9% | 23.1% |
| Hypothermia | 30.0% | 27.0% | 14.3% | 57.1% | 67.0%
| 13.0% | 52.4%
| 19.0% |
*: p < 0.05, NABIS: H: the National Acute Brain Injury Study: Hypothermia.
Protective mechanism point and complication of hypothermia therapy
| Point of protective mechanism |
| Glutamate acid release |
| Calcium-dependent cascade |
| Cerebral metabolism |
| Reactive oxygen species and NO production |
| Apoptosis |
| The blood-brain barrier disturbance |
| Complication |
| Infection |
| Electrolyte abnormality |
| Thrombocytopenia |
| Arrhythmia |
| Reduction of the cardiac output |
| Liver dysfunction |
| Renal dysfunction |
| Gastrointestinal dysfunction |
| Hyperglycemia |